Natural killer (NK) cells play an important role in the immunosurveillance of hematopoietic malignancies. Their reactivity is influenced by activating and inhibitory signals mediated by tumor-expressed ligands for NK receptors. Many members of the tumor necrosis factor (TNF) family modulate differentiation, proliferation, activation and death of both tumor and immune effector cells. The TNF receptor family member glucocorticoid-induced TNFR-related protein (GITR) stimulates anti-tumor immunity in mice, but available data indicate that GITR may mediate different effects in mice and men and impairs the reactivity of human NK cells. Here, we comprehensively studied the expression and function of GITR ligand (GITRL) in leukemia. Among the different leukemia entities, pronounced expression of GITRL on leukemic cells was observed in chronic lymphocytic leukemia (CLL), and the GITR receptor was expressed at significantly higher levels on NK cells of CLL patients compared with healthy controls. Upon GITR --GITRL interaction, signaling via GITRL into the leukemia cells induced the release of interleukin (IL)-6, IL-8 and TNF, which act as growth and survival factors for CLL cells. In addition, GITRL impaired both direct and Rituximab-induced degranulation, cytotoxicity and interferon-g production of NK cells, which could be restored by GITR blocking antibodies. Thus, GITRL may contribute to disease pathophysiology and resistance to direct and Rituximab-induced NK reactivity in CLL.
INTRODUCTION
The molecular mechanisms governing the reciprocal interaction of transformed cells with the immune system not only influence whether a clinically apparent malignancy develops or not; they also influence disease progression and the success of treatment strategies relying on immune activation. 1 Many members of the tumor necrosis factor (TNF)/TNF receptor (TNFR) family influence host --tumor interaction by governing differentiation, proliferation, activation and death of both tumor and immune effector cells. 2 The TNFR family member glucocorticoid-induced TNFR-related protein (GITR, TNFRSF18) and its ligand (GITRL) modulate a great variety of physiological and pathophysiological conditions. Initially considered an inhibitor of regulatory T-cell (Treg) activity, GITR and its ligand are meanwhile known to affect multiple different cell types, and the role of this molecule system in immune responses in general and anti-tumor immunity in particular has received considerable interest (for review Nocentini and Riccardi 3 ; Shevach and Stephens 4 ; Placke et al. 5 ) In mouse tumor models, GITR stimulation influences animal survival and can even lead to the eradication of tumors, which has mainly been attributed to induction of T-cell immunity.
6 --14 However, we and others recently provided evidence that GITR inhibits effector functions of human natural killer (NK) cells and impairs their anti-tumor reactivity. 15 --18 NK cells are cytotoxic lymphocytes that have a major role in anti-tumor immunity. 19 They also contribute to the clinical efficacy of therapeutic monoclonal antibodies such as Rituximab, which is meanwhile an essential component of most treatment strategies for B-cell lymphoma. 20 Beside mediating apoptotic cell death, induction of Fc-dependent effector mechanisms such as complement-and antibody-dependent cellular cytotoxicity (ADCC) is considered critical for the clinical success of this therapeutic antibody. 21 In chronic lymphocytic leukemia (CLL), the ability of NK cells to target malignant cells upon application of Rituximab is compromised, and overcoming this immune dysfunction holds promise to increase the therapeutic efficacy of this and other anti-CD20 antibodies. 22 --25 As (i) NK cells constitutively express GITR at the cell surface and expression is increased upon activation, (ii) GITRL is expressed on murine B cells, but also on various tumor types including acute myeloid leukemia (AML), (iii) GITRL itself can transduce signals causing release of cytokines by malignant cells and (iv) GITR --GITRL interaction impairs the reactivity of human NK cells, 15 --18,26 we here studied the expression and function of GITRL in B-CLL with a focus on its influence on direct and Rituximabinduced NK reactivity.
PATIENTS AND METHODS

Patients
Peripheral blood mononuclear cells (PBMC) and serum from leukemia patients as well as clinical data were acquired at the time of diagnosis before therapy. All patients declared written informed consent in accordance with the Helsinki protocol, and the study was performed according to the guidelines of the local Ethics Committee. Diagnosis was confirmed by study of bone marrow specimens and flow cytometric immunophenotyping.
Antibodies and fusion proteins The anti-human GITR monoclonal antibody (clone 110416) with defined capacity to block GITR --GITRL interaction, 15 anti-GITRL (clone 109101), GITR-Ig fusion protein and immunoglobulin (Ig)G1 isotype controls were obtained from R&D Systems (Wiesbaden, Germany). The goat anti-mouse phycoerythrin conjugate was from Jackson Immunoresearch (West Grove, PA, USA). CD3, CD5, CD19, CD27, CD33, CD34, CD56, CD69, CD107a, human leukocyte antigen-ABC and IgM fluorescence conjugates and isotype controls were from BD Pharmingen (San Diego, CA, USA). Rituximab (MabThera, Roche, Basel, Switzerland) was obtained internally at the Eberhard Karls University. All other reagents were from Sigma (St Louis, MO, USA).
Preparation of NK cells Polyclonal NK cells were generated by incubation of non-plasticadherent PBMC with irradiated RPMI8866 feeder cells over 10 days as described previously. 15 Functional experiments were performed when NK cell purity was 490% as determined by flow cytometry.
Flow cytometry Cells were stained by incubation with GITR and GITRL monoclonal antibody or isotype control followed by goat antimouse-phycoerythrin as secondary reagent and human leukocyte antigen-ABC conjugates. NK cells, B-CLL cells, AML cells and acute lymphocytic leukemia (ALL) cells among PBMC were selected by
Chronic myeloid leukemia (CML) cells were selected by forward/ sideward scatter. Total B cells among PBMC of healthy donors were selected by staining for CD19, B-cell subsets were identified as follows:
Fluorescence-activated cell sorting analysis was performed using a FC500 (Beckman Coulter, Krefeld, Germany). Specific fluorescence indices were calculated by dividing median fluorescence obtained with the respective specific monoclonal antibody by median fluorescence obtained with the corresponding isotype control.
Cytotoxicity assays Direct cytotoxicity and ADCC of NK cells against leukemia cells were analyzed by 2 h BATDA Europium assays as described previously. 17 Percentage of lysis was calculated as follows: 100 Â (experimental releaseÀspontaneous release)/(maximum releaseÀspontaneous release).
Determination of cytokine levels Interferon-g, interleukin (IL)-6, IL-8 and TNF levels in supernatants were determined by enzyme-linked immunosorbent assay according to the manufacturer's instructions using OptEIA sets from BD Pharmingen or DuoSet enzyme-linked immunosorbent assay development systems from R&D Systems. Data shown are means of triplicate measurements. Cytokine levels in sera of patients and healthy donors were determined by IMMULITE (Siemens, Eschborn, Germany) measurement.
RESULTS
GITRL is expressed more frequently and at high levels in CLL as compared with other leukemia entities or healthy B cells As a first step we analyzed GITRL expression on primary human B-CLL cells from a total of 60 patients. Surface levels of human leukocyte antigen class I and GITR were also determined. The clinical characteristics of each investigated patient are given in Figure 1a and data not shown). GITRL and GITR were also detectable on mRNA level by reverse transcription-PCR analysis of CLL samples. Notably, GITRL and GITR mRNA expression was also observed in CLL cells that did not expresss relevant levels of the respective molecules on the cell surface (data not shown). This indicates that GITRL and GITR expression on CLL cells, alike reported for other disease entities and for other TNF/TNFR family members, may be regulated posttranscriptionally. 5 As GITRL was found to be expressed by AML cells 17 we next compared the proportion of GITRL-positive cases and the GITRL expression levels in CLL to that detectable in AML. Leukemic cells of patients with ALL and CML, for which no information regarding GITRL expression was yet available, were also studied. Fluorescence-activated cell sorting analysis of primary leukemic cells of patients with AML (n ¼ 109), ALL (n ¼ 32) and CML (n ¼ 12) revealed substantial expression of GITRL in 52%, 53% and 43% of the investigated cases, respectively (Figure 1b Together, these results demonstrate that GITRL is expressed on leukemic cells in a high percentage of all four investigated disease entities. Expression was observed most frequently in CLL among the four investigated leukemia entities, and GITRL levels were significantly higher on malignant CLL cells as compared with B cells of healthy donors. On the basis of phenotypic analysis, this points to an important role of GITRL in CLL pathophysiology.
GITRL stimulates the release of IL-6, IL-8 and TNF by CLL cells, and elevated levels of these cytokines are contained in sera of CLL patients Next, we studied whether the GITRL expressed by CLL cells was functional and capable to transduce signals into the leukemia cells. This was of interest because GITRL signaling has been shown to modulate the release of various cytokines including TNF and IL-8, which are associated with prognosis of CLL patients, by other cell types. 17,27 --30 To study whether GITRL influenced cytokine production of CLL cells, leukemic cells of patients were cultured alone, on immobilized GITR-Ig (which enables multimerization of GITRL) or isotype control. As CLL cells can coexpress GITRL and GITR we performed these experiments with GITRL þ GITR þ , GITRL þ GITRÀ and GITR --GITRLÀ CLL cells. Analysis of the culture supernatants by enzyme-linked immunosorbent assay revealed that the presence of GITR-Ig significantly (all Po0.05, Student's t-test) enhanced the release of IL-6, IL-8 and TNF by both GITRL þ GITR þ (Figure 2a ) and GITRL þ GITR- (Figure 2b ) CLL cells. No effects were observed when GITRL was not expressed (Figure 2c) . In a further set of experiments we preincubated GITRL þ GITR þ CLL cells with GITR antibody with defined capacity to block GITR --GITRL interaction 15 followed by washing and incubation on immobilized GITR-Ig. In the absence of GITR-Ig, cytokine production of GITRL þ GITR þ CLL cells was not affected by the blocking GITR antibody. Upon culture on GITR-Ig, pretreatment with the GITR antibody had either no effect or caused a slight reduction of cytokine production that was not statistically significant (Figure 2d ). This confirmed that GITR-Iginduced cytokine production by induction of signaling via CLL-expressed GITRL, at least in great part. Considering the association of IL-6, IL-8 and TNF with CLL pathophysiology 28 --31 we next studied the levels of these cytokines in CLL patient sera (Table 1) . Compared with sera of healthy controls, significantly (all Po0.05, Student's t-test) higher levels of IL-6, IL-8 and TNF were contained in the sera of the CLL patients enrolled in our study (Figure 3a) . Thus, signaling via GITRL may enable CLL cells to release immunomodulatory cytokines, which are contained at elevated levels in CLL patient sera. Next, we analyzed whether cytokine levels in a given patient's serum correlated with GITRL or GITR expression on CLL cells of the respective patient. However, as shown in the Figures 3b and c , neither IL-6, IL-8 or TNF levels in the sera of the patients enrolled in our study correlated (Pearson's correlation) with GITRL or GITR surface levels on their leukemic cells. Furthermore, no correlation (one-way analysis of variance) of GITRL or GITR expression on leukemic cells with the stage of the patient's disease according to Binet classification was observed (Figure 3d ).
CLL-expressed GITRL impairs direct and Rituximab-induced NK reactivity
Considering the NK inhibitory role of GITR in humans we next determined the effect of CLL-expressed GITRL on the antileukemia reactivity of allogenic NK cells. Disruption of GITR --GITRL interaction by our GITR blocking antibody significantly (all Po0.05, Student's t-test) increased the cytotoxicity and interferon-g production of allogenic NK cells in cultures with GITRL-positive primary CLL cells. Moreover, blocking GITR --GITRL interaction also enhanced Rituximab-induced NK reactivity against GITRL-positive CLL cells. Both cytotoxicity and cytokine production in cultures with CLL targets varied substantially with NK cells of different donors, but in all experiments exposure of CLL cells to Rituximab clearly induced ADCC and interferon-g production. Both ADCC and cytokine production of NK cells were significantly (all Po0.05, Student's t-test) further increased by blocking GITR on NK cells (Figures 4a and b) . The possibility to enhance both direct and Rituximab-induced NK reactivity by blocking GITR --GITRL interaction was also observed in analyses of CD107a expression as marker for granule mobilization in cultures of primary CLL cells with NK cells among freshly isolated PBMC of allogenic healthy donors (Figure 4c ). This confirmed both the NK-inhibitory effect of CLL-expressed GITRL and the validity of CD107a expression as surrogate marker for NK reactivity, which enabled subsequent ex vivo analyses directly with PBMC of CLL patients. GITRL þ GITR þ CLL cells were incubated for 1 h alone or in the presence of blocking GITR antibody or isotype control followed by washing before culture and collection of supernatants as described above. *Statistically significant differences.
GITR is upregulated on NK cells of CLL patients and inhibits NK reactivity by interacting with its CLL-expressed ligand Because NK cells constitutively express low levels of GITR, and expression is upregulated upon activation 15, 18, 32 we next determined the levels of GITR and the activation marker CD69 on NK cells of our CLL patients and healthy controls by fluorescenceactivated cell sorting. Compared with the low GITR expression on NK cells of healthy donors, which displayed a resting (that is, CD69 negative) phenotype, NK cells of the CLL patients displayed significantly (Po0.05, Student's t-test) enhanced expression of GITR and CD69 (Figure 5a ). Next, we determined the effect of GITR --GITRL interaction on granule mobilization of autologous NK cells among PBMC of CLL patients. GITR blockade resulted in significantly enhanced NK cell degranulation, and this was observed both with regard to direct and Rituximab-induced NK anti-leukemia reactivity (both Po0.05, Student's t-test). Alike in the allogenic setting, substantial variation with regard to the effects of both Rituximab and GITR blockade on the reactivity of autologous NK cells was observed among individual patients. 
DISCUSSION
In this study, we analyzed the expression and function of the TNF family member GITRL in CLL. GITRL was expressed significantly more often on leukemic cells of CLL patients than in patients with AML, ALL or CML. Moreover, NK cells of CLL patients were found to express significantly upregulated levels of its counterpart GITR. Upon GITR --GITRL interaction, signals via GITRL into CLL cells lead to release of IL-6, IL-8 and TNF, which all have been described to act as autocrine/paracrine growth and survival signals in CLL. 28 --31 In addition, forward signaling by CLL-expressed GITRL impaired direct and Rituximab-induced reactivity of allogenic and autologous NK cells. Our data indicate that high level GITRL expression may contribute to CLL pathophysiology and can impair direct and Rituximab-induced NK cell responses, which have been reported to be compromised in CLL patients. 22 --25 GITRL is generally known as ligand of the T-cell costimulatory molecule GITR and mainly is expressed on antigen-presenting cells. 33 We reported previously that tumor cell lines and some primary malignant cells of various origins including AML cells can express functional GITRL. 15, 17 Our analysis of GITRL expression in a total of 213 leukemia cases reported here revealed that GITRL is expressed on primary leukemic cells in 78% of B-CLL patients and thus a significantly higher proportion than observed with other leukemia entities (52%, 53% and 43% in AML, ALL and CML, respectively). GITRL levels on primary CLL cells were similar to those detected in AML, where GITRL expression is associated with monocytic differentiation, 17 but significantly higher than that expressed on primary ALL and CML cells. Notably, GITRL expression levels in CLL were also significantly higher as compared with B cells of healthy donors, which suggested that enhanced GITRL expression may have a role in CLL pathophysiology.
Previous studies by us and others revealed that GITRL signaling alters the cytokine production of healthy myeloid cells, but also of carcinoma cell lines and AML cells. 15, 17, 27 The results presented in our study extend this knowledge to malignant B cells.
Our experiments with GITRL þ GITR-and GITRL-negative CLL cells and utilizing GITRL þ GITR þ CLL cells pretreated with blocking anti-GITR antibody provide clear evidence that the effects of GITRIg on CLL cell cytokine production are, at least in great part, due to induction of GITRL signaling. IL-6, IL-8 and TNF, which are released by CLL cells upon GITRL signaling, enhance proliferation and survival of the leukemic lymphocytes in an autocrine/paracrine manner and correlate with disease characteristics and shorter survival of B-CLL patients. 28 --31 In line with the results of previous studies we found that the sera of the CLL patients enrolled in our study contained significantly elevated levels of all three cytokines. By stimulating the release of IL-6, IL-8 and/or TNF by the CLL cells GITRL may thus contribute to CLL pathophysiology. A similar function has been reported for other TNF family members such as RANKL, BAFF and APRIL, for which a pathophysiological role in CLL already has been postulated. 34 --37 Of note, GITRL expression levels on CLL cells did neither correlate with the cytokine levels in the respective patient's sera nor with the diseases stage. However, to our opinion this does not contradict an important role of GITRL in CLL pathophysiology for the following reasons: (i) there is clear evidence that expression levels of GITRL and other TNF superfamily members do not necessarily correlate with their ability to transduce signals; 8 (ii) regulatory or mutational blockade/induction of GITRL surface expression and/or signaling may occur during the development and progression of the disease; (iii) GITRL is not the only mediator of cytokine production by CLL cells and other mechanisms including signaling via other CLL-expressed TNF family members certainly contribute to the same.
Beside signaling into the ligand expressing cells, GITRL also transduces forward signals, which affects the function of the different cell types expressing its counterpart GITR. The latter is mainly known for its role in Treg, where it is thought to exert two seemingly opposite functions: inhibition of suppressive capacity and stimulation of proliferation (for review Shevach and Stephens 4 ; Placke et al. 5 ; Nocentini et al. 33 ) Although the pronounced expression of GITRL in CLL patients can thus be reconciled with available data demonstrating that Treg numbers are increased in CLL patients, it seems surprising that immune responses including Rituximab-induced NK reactivity have been reported to be impaired by enhanced Treg suppression in this disease. 38 --41 This is even more because data from various mouse tumor models demonstrated that GITR triggering stimulated anti-tumor immunity, which was attributed to abrogation of Treg suppression and/or costimulation of effector T cells. 4, 5, 33 A potential explanation could be provided by available data indicating that, in contrast to the murine system, human Treg maintain their suppressive function after GITR triggering, suggesting that GITR may mediate different effects in mice and men. 42, 43 On the other hand, a recent study by Bianchini et al. 44 identified a GITR-expressing human Treg population with potent suppressive activity that was inhibited by anti-GITR antibody. Certainly more work is needed to fully elucidate the role of GITR in immunity and its therapeutic modulation as a potential strategy to stimulate T cells for tumor therapy. This is even more because the results regarding the consequences of GITR stimulation on different T-cell subsets and with different tumor models have been found to be influenced by the time of intervention, the biological environment and the level of the ongoing immune response. 4, 5 Moreover, even if GITR stimulation may be suitable to stimulate adaptive anti-tumor immunity, it needs to be considered that GITR and its ligand cause bidirectional signal transduction and have meanwhile been found to modulate the reactivity of various Although a stimulatory role of GITR for NK cells in the interaction with DC has been reported, 32 data by us and others revealed that GITR rather is a negative regulator for NK cell activation and inhibits their reactivity upon interaction with its tumor-expressed ligand. 15 --18 In line we demonstrate in this study that GITRL on CLL cells impairs direct and Rituximab-induced NK cell granule mobilization, ADCC and interferon-g production. The latter cytokine participates in cancer elimination by inhibiting cellular proliferation and angiogenesis, promoting apoptosis, stimulating the adaptive immune system and is instrumental for enhancing antigen processing and presentation for recognition by effector T cells. 45 Importantly, disruption of GITR --GITRL interaction not only reinforced NK reactivity in analyses with allogenic NK cells, but also enhanced both direct and Rituximab-induced NK anti-tumor responses in an autologous setting using PBMC directly obtained from CLL patients ex vivo. Thus, GITRL on primary CLL cells may, beside contributing to a pathophysiologically favorable cytokine milieu by reverse signaling, additionally impair anti-tumor immunity by mediating inhibitory 'forward' signals in NK cells.
NK reactivity and the influence of GITRL varied substantially among different patients, which is fully in line with the notion that NK reactivity is influenced by a balance of multiple activating and inhibitory signals. 19 For induction of NK reactivity by therapeutic antibodies such as Rituximab, triggering of FcgRIIIA certainly constitutes the central mechanism. However, NK responses may still be dampened by signals mediated by tumor-expressed ligands for inhibitory NK receptors. Our study not only elucidates a molecular mechanism potentially contributing to the impairment of direct and Rituximab-induced NK cell responses in CLL patients; our data also suggest that shifting the balance of NK-modulatory signals toward activation by preventing interaction of CLL-expressed GITRL with GITR on NK cells may serve well to reinforce Rituximab-induced NK reactivity. This is even more because recognition of tumor targets and FcgRIIIA triggering leads to activation of NK cells and GITR is upregulated on NK cells upon activation. 15, 46 In line, the NK cells of the CLL patients in our study displayed an activated phenotype with significantly enhanced expression of GITR, which may contribute further to impaired NK reactivity in CLL. This notion is supported by multiple studies reporting on altered NK receptor expression as reason for impaired anti-tumor immunity in cancer patients. This was observed with other members of the TNF/TNFR family such as 4-1BB, which is closely related to GITR, but also with NK receptors belonging to other protein families (for example, Baessler et al. 47 and Groh et al. 48 ). Presently, multiple strategies are used to enhance the efficacy of CD20 antibody treatment of cancer, and many approaches focus on novel antibody variants with markedly improved ADCC activity. 25, 49, 50 Beside increasing the immunostimulatory capacity of an antibody itself it may also be feasible to enhance its therapeutic efficacy by preventing mechanisms, which enable tumor immunosubversion. This appears particularly relevant in CLL, where antibody-dependent effector functions of cells of the innate immune system are impaired. 25 Our data suggest that disruption of GITR --GITRL interaction may be a promising approach to reinforce the efficacy of Rituximab to induce NK cell reactivity in CLL. However, potential immunoinhibitory effects on T cells need to taken into account when considering therapeutic GITR blocking to reinforce NK reactivity. Further studies are certainly warranted in the transition of GITR modulating reagents from preclinical work to the treatment of patients with CLL and other cancers.
